Kaul Samir
Known title: 10% OwnerCIK: 0001501915
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NXDR Sets Q3 2026 Earnings Date, Highlights Community Events. Nextdoor set a date for its Q3 2026 earnings release and conference call, giving shareholders a clear timeline. The company also highlighted its holiday treat map for Canadians and announced 2026 Fave Award winners, showing community engagement. A note on its listing status clarifies that a switch to a different exchange does not automatically move it to a faster trading tier. These updates give context to the company's focus and upcoming earnings.
Transaction History
| GH | ▲ Buy | Option Exercise | 5,531 | $0 | 6/14/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 1,814 | $0 | 6/15/2022 | View on chart |
| NXDR | ▼ Sell | Other | 10,232,269 | — | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target
Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.